Home - Translational Lung Cancer Research

New Impact Factor for Translational Lung Cancer Research: 4.726

We are pleased to announce that the Translational Lung Cancer Research (TLCR) has attained its latest impact factor update for the 2021 citation year: 4.726.

Interviews with Outstanding Authors (2022)

In 2022, many authors make outstanding contributions to our journal. Their articles published with us have received very well feedback in the field and stimulate a lot of discussions and new insights among the peers.

Hereby, we would like to highlight some of our outstanding authors, with a brief interview of their thoughts and insights as authors. Allow us to express our heartfelt gratitude for their tremendous effort and valuable contributions to the scientific process.

ALK-Positive NSCLC (Ongoing)

This special series on “ALK-Positive NSCLC” is edited by Dr. Justin F. Gainor and Dr. Jessica J. Lin from the Department of Medicine, Harvard Medical School, Boston, USA. This special series aims to provide an updated overview of the most recent acquisitions and future perspectives.

TLCR Annual Report 2021

Welcome to the 2021 annual report for Translational Lung Cancer Research. In 2021, the TLCR has continued its mission to increase the quality and impact of the journal, and to provide readers with a novel, well-organized, informative, enlightening and educational journal.

We would like to sincerely thank our Editorial Board Members, Guest editors, Reviewers, Authors, Readers for all your supports and contributions to TLCR in 2021, and we look forward to continuing our work with you in the new year.

Reviewer of the Month (2022)

In 2022, TLCR reviewers continue to make outstanding contributions to the peer review process. They demonstrated professional effort and enthusiasm in their reviews and provided comments that genuinely help the authors to enhance their work.

Hereby, we would like to highlight some of our outstanding reviewers, with a brief interview of their thoughts and insights as a reviewer. Allow us to express our heartfelt gratitude for their tremendous effort and valuable contributions to the scientific process.

‹ ›

Vol 11, No 8 (August, 2022)

About tlcr

Manuscript Submission

AME Editing Service

Reprint & Permission

Advertising

Contact us

General editorial enquiries:
Email: editor@tlcr.org
Copyright related contact:
Email: permissions@amegroups.com
Commercial Sales contact (Reprints, advertising, etc.):
Email: sales@amegroups.com

TLCR Chinese Edition more

免疫治疗是晚期非小细胞肺癌去化疗的关键，或还是未到时候？

免疫检查点抑制剂（immune checkpoint... More >>

晚期或转移性非小细胞肺癌一线免疫治疗中，肿瘤细胞PD-L1表达的阈值究竟在哪

对于晚期或转移性非小细胞肺癌（non-small cell lung... More >>

KEYNOTE-042研究：降低帕博利珠单抗单药一线治疗的PD-L1阈值是个好主意吗？

在针对程序性死亡1（programmed death 1，PD-1）或程序性死亡配体1（programmed... More >>

Editorial

Kisspeptins and norepinephrine regulate different G-protein-coupled receptor signaling pathways

Rafael Rosell, María González-Cao, Masaoki Ito, Mireia Marco Jordan, José Luis Gómez-Vázquez, Jing-Hua Chen, Andrés Aguilar, Imane Chaib

PDF Pages: 1517-1521 Full Text (551) COI Form Open Access

Circulating mitochondrial DNA as a biomarker for lung cancer screening

Mitchell S. von Itzstein, David E. Gerber, John D. Minna

PDF Pages: 1522-1525 Full Text (188) COI Form Open Access

Original Article

Prognostic implications of cellular senescence in resected non-small cell lung cancer

Andreas Domen, Christophe Deben, Ines De Pauw, Christophe Hermans, Hilde Lambrechts, Jasper Verswyvel, Vasiliki Siozopoulou, Patrick Pauwels, Marco Demaria, Mick van de Wiel, Annelies Janssens, Jeroen M. H. Hendriks, Paul Van Schil, Jan B. Vermorken, Timon Vandamme, Hans Prenen, Marc Peeters, Filip Lardon, An Wouters

PDF Pages: 1526-1539 Full Text (429) Reporting Checklist Data Sharing Statement Peer Review File COI Form Open Access

A new N descriptor for non-small cell lung cancer: the classification based on anatomic location, number and ratio of metastatic lymph nodes

Bolun Zhou, Ruochuan Zang, Moyan Zhang, Peng Song, Lei Liu, Fenglong Bie, Yue Peng, Guangyu Bai, Shugeng Gao

PDF Pages: 1540-1554 Full Text (211) Reporting Checklist COI Form Open Access

Safety and efficacy of retreatment with immune checkpoint inhibitors in non-small cell lung cancer: a systematic review and meta-analysis

Zijing Cai, Ping Zhan, Yong Song, Hongbing Liu, Tangfeng Lv

PDF Pages: 1555-1566 Full Text (319) Reporting Checklist Peer Review File COI Form Open Access

First-in-human results of targeted intraoperative molecular imaging for visualization of ground glass opacities during robotic pulmonary resection

Gregory T. Kennedy, Feredun S. Azari, Elizabeth Bernstein, Isvita Marfatia, Azra Din, Charuhas Deshpande, Nikki Galvis, Jonathan Sorger, John C. Kucharczuk, Sunil Singhal

PDF Pages: 1567-1577 Full Text (189) Reporting Checklist Data Sharing Statement COI Form Open Access

Tumor volume as a predictor of cell free DNA mutation detection in advanced non-small cell lung cancer

Justin M. Haseltine, Michael Offin, Jessica R. Flynn, Zhigang Zhang, Emily S. Lebow, Khaled Aziz, Alex Makhnin, Jordan Eichholz, Lee P. Lim, Mark Li, James M. Isbell, Daniel R. Gomez, Bob T. Li, Andreas Rimner

PDF Pages: 1578-1590 Full Text (241) Reporting Checklist Data Sharing Statement Peer Review File COI Form Open Access

Survival of 7,311 lung cancer patients by pathological stage and histological classification: a multicenter hospital-based study in China

Siyi He, He Li, Maomao Cao, Dianqin Sun, Fan Yang, Xinxin Yan, Shaoli Zhang, Yutong He, Lingbin Du, Xibin Sun, Ning Wang, Min Zhang, Kuangrong Wei, Lin Lei, Changfa Xia, Ji Peng, Wanqing Chen

PDF Pages: 1591-1605 Full Text (193) Reporting Checklist Data Sharing Statement Peer Review File COI Form Open Access

Open-label, multi-center, phase II study of adjuvant pemetrexed plus cisplatin for completely resected stage IB to IIIA adenocarcinoma of the lung: APICAL trial

Cheol-Kyu Park, Hyung-Joo Oh, Seung Soo Yoo, Shin Yup Lee, Sang Hoon Lee, Eun Young Kim, Sung Yong Lee, Juwhan Choi, Min Ki Lee, Mi-Hyun Kim, Tae Won Jang, Chaeuk Chung, In-Jae Oh, Young-Chul Kim

PDF Pages: 1606-1618 Full Text (211) Reporting Checklist Data Sharing Statement Peer Review File COI Form Open Access

A retrospective study for prognostic significance of type II diabetes mellitus and hemoglobin A1c levels in non-small cell lung cancer patients treated with pembrolizumab

Yinchen Shen, Jiaqi Li, Huiping Qiang, Yuqiong Lei, Qing Chang, Runbo Zhong, Giulia Maria Stella, Francesco Gelsomino, Yeon Wook Kim, Afaf Abed, Jialin Qian, Tianqing Chu

PDF Pages: 1619-1630 Full Text (260) Reporting Checklist Data Sharing Statement COI Form Open Access

Efficacy evaluation of surgery combined with chemotherapy for stage IIIA small cell lung cancer patients: a retrospective analysis

Dongliang Bian, Siming Jiang, Yicheng Xiong, Mengfan Qi, Jiawei Wu, Alfredo Addeo, Yoshikane Yamauchi, Farkhad Manapov, Wolfram C. M. Dempke, Jacopo Vannucci, Alessandro Di Federico, Xiaoxiong Xu, Linsong Chen

PDF Pages: 1631-1642 Full Text (178) Reporting Checklist Data Sharing Statement COI Form Open Access

Clinical use of ¹⁸F-FDG PET/CT in the differential diagnosis of patients with primary and secondary adenoid cystic carcinoma of the lung: a retrospective cohort study

Xiaolin Sun, Weiqing Gu, Hui Yuan, Siyun Wang, Yang Yang, Laura Evangelista, Liyan Zhang, Lei Jiang

PDF Pages: 1643-1656 Full Text (155) Reporting Checklist Data Sharing Statement COI Form Open Access

Efficacy and safety of anlotinib combined with carboplatin and pemetrexed as first-line induction therapy followed by anlotinib plus pemetrexed as maintenance therapy in EGFR/ALK wild-type advanced non-squamous non-small cell lung cancer in China: a multicenter, single-arm trial

Zhen He, Xiuli Yang, Tianjiang Ma, Qiumin Yang, Chenghui Zhang, Yunfang Chen, Pengyuan Wang, Armida D’Incecco, Giulio Metro, Shugo Uematsu, Qiming Wang

PDF Pages: 1657-1666 Full Text (206) Reporting Checklist Data Sharing Statement COI Form Open Access

The incidence and risk factors of acute pain after preoperative needle localization of pulmonary nodules: a cross-sectional study

Wen Qin, Jun Ge, Zhihao Gong, Yunyun Zhang, David M. DiBardino, Andrea Imperatori, Yasmeen K. Tandon, Masahiro Yanagiya, Feng Yao, Yuwei Qiu

PDF Pages: 1667-1677 Full Text (219) Reporting Checklist Data Sharing Statement COI Form Open Access

Development and validation of a dynamic survival nomogram for metastatic non-small cell lung cancer based on the SEER database and an external validation cohort

Qing Wang, Yansu Wang, Xinyu Wang, Yusuke Nakamura, Per Hydbring, Yoshikane Yamauchi, Xiaojing Zhao, Min Cao

PDF Pages: 1678-1691 Full Text (242) Reporting Checklist Data Sharing Statement COI Form Open Access

Comparison of operation time, efficacy and safety between through-the-scope stent and over-the-while stent in malignant central airway obstruction: a multi-center randomized control trial

Da-Xiong Zeng, Zhao-Zhong Cheng, Xue-Dong Lv, Cheng-Shui Chen, Ji-Wang Wang, Robert Browning, Ko-Pen Wang, Jian-An Huang, Hervé Dutau, Fayez Kheir, Ming-Yao Ke, Jun-Hong Jiang

PDF Pages: 1692-1701 Full Text (201) Reporting Checklist Trial Protocol Data Sharing Statement COI Form Open Access

The improved success rate and reduced complications of a novel localization device vs. hookwire for thoracoscopic resection of small pulmonary nodules: a single-center, open-label, randomized clinical trial

Liwen Fan, Wenyan Ma, Jie Ma, Longtang Yang, Zhexin Wang, Ke Xu, Yunxuan Jia, Beibei Sun, Jessica C. Sieren, Haitang Yang, Feng Yao

PDF Pages: 1702-1712 Full Text (122) Reporting Checklist Trial Protocol Data Sharing Statement COI Form Open Access

iMDT Corner

Locally advanced undifferentiated small round cell sarcoma of the lung with novel SDCCAG8-AKT3 fusion and type II tumor immunity in the microenvironment: a rare case report

Lin Huang, Changlong Qin, Dan Pu, Yanyang Liu, Massimiliano Bassi, Lukas Käsmann, Lu Li

PDF Pages: 1713-1721 Full Text (245) Reporting Checklist COI Form Open Access

Editorial Commentary

Limited-anatomic resection for ground-glass like lung cancer—simplicity does not mean inefficacy

Qiuyuan Li, Kaiqi Jin, Jie Dai, Yang Yang, Gening Jiang

PDF Pages: 1722-1724 Full Text (102) Peer Review File COI Form Open Access

Letter to the Editor

PD-L1 expression in pulmonary lymphoepithelioma-like carcinoma: is it a prognostic biomarker?

Wen Li, Xinyue Zhang, Jianping Huang, Yinghong Yang

PDF Pages: 1725-1726 Full Text (129) COI Form Open Access

Implementation of programmed death-ligand 1 (PD-L1) expression as a prognostic biomarker for patients with lung cancer

Huijuan Li, Dang Lin, Tangfeng Lv

PDF Pages: 1727-1730 Full Text (149) COI Form Open Access

Erratum

Erratum to identification of GPX4 as a therapeutic target for lung adenocarcinoma after EGFR-TKI resistance

Editorial Office

PDF Pages: 1731-1733 Full Text (118) Open Access

Review Article

Targeted therapy for non-small cell lung cancer: current standards and the promise of the future

Bryan A. Chan, Brett G.M. Hughes

Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer

Takashi Kohno, Takashi Nakaoku, Koji Tsuta, Katsuya Tsuchihara, Shingo Matsumoto, Kiyotaka Yoh, Koichi Goto

Global trends of lung cancer mortality and smoking prevalence

Farhad Islami, Lindsey A. Torre, Ahmedin Jemal

Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations—a review

Erin L. Stewart, Samuel Zhixing Tan, Geoffrey Liu, Ming-Sound Tsao

Tackling ALK in non-small cell lung cancer: the role of novel inhibitors

Francesco Facchinetti, Marcello Tiseo, Massimo Di Maio, Paolo Graziano, Emilio Bria, Giulio Rossi, Silvia Novello

Circulating tumor cells versus circulating tumor DNA in lung cancer—which one will win?

Silvia Calabuig-Fariñas, Eloísa Jantus-Lewintre, Alejandro Herreros-Pomares, Carlos Camps

Editorial

Whacking a mole-cule: clinical activity and mechanisms of resistance to third generation EGFR inhibitors in EGFR mutated lung cancers with EGFR-T790M

Daniel B. Costa, Susumu S. Kobayashi

Review Articles

Management of ground-glass opacities: should all pulmonary lesions with ground-glass opacity be surgically resected?

Yoshihisa Kobayashi, Tetsuya Mitsudomi

KRAS mutant NSCLC, a new opportunity for the synthetic lethality therapeutic approach

Javier de Castro Carpeño, Cristóbal Belda-Iniesta

Review Article on Lung Cancer Diagnostics and Treatments 2015: A Renaissance of Patient Care

Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities

Jeryl Villadolid, Asim Amin

Review Article

Targeted therapy for non-small cell lung cancer: current standards and the promise of the future

Bryan A. Chan, Brett G.M. Hughes

Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations—a review

Erin L. Stewart, Samuel Zhixing Tan, Geoffrey Liu, Ming-Sound Tsao

Global trends of lung cancer mortality and smoking prevalence

Farhad Islami, Lindsey A. Torre, Ahmedin Jemal

Recurrence after surgery in patients with NSCLC

Hidetaka Uramoto, Fumihiro Tanaka

Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer

Takashi Kohno, Takashi Nakaoku, Koji Tsuta, Katsuya Tsuchihara, Shingo Matsumoto, Kiyotaka Yoh, Koichi Goto

Non-small cell lung cancer: current treatment and future advances

Cecilia Zappa, Shaker A. Mousa

Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin (PI3K-Akt-mTOR) signaling pathway in non-small cell lung cancer

Po Yee Yip

Lung cancer molecular epidemiology in China: recent trends

Caicun Zhou

The role of the immune system in non-small cell lung carcinoma and potential for therapeutic intervention

Joanna Domagala-Kulawik

Concordance of IHC, FISH and RT-PCR for EML4-ALK rearrangements

Cristina Teixidó, Niki Karachaliou, Vicente Peg, Ana Gimenez-Capitan, Rafael Rosell

ALK and crizotinib: after the honeymoon…what else? Resistance mechanisms and new therapies to overcome it

Christian Rolfo, Francesco Passiglia, Marta Castiglia, Luis E. Raez, Paul Germonpre, Ignacio Gil-Bazo, Karen Zwaenepoel, Annemieke De Wilde, Giuseppe Bronte, Antonio Russo, Jan P. Van Meerbeeck, Paul Van Schil, Patrick Pauwels

Highlighted Reports in European Lung Cancer Conference

Preoperative mediastinal lymph node staging for non-small cell lung cancer: 2014 update of the 2007 ESTS guidelines

Paul De Leyn, Christophe Dooms, Jaroslaw Kuzdzal, Didier Lardinois, Bernward Passlick, Ramon Rami-Porta, Akif Turna, Paul Van Schil, Frederico Venuta, David Waller, Walter Weder, Marcin Zielinski

Review Article on Lung Cancer Diagnostics and Treatments 2015: A Renaissance of Patient Care

Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities

Jeryl Villadolid, Asim Amin

Circulating DNA in diagnosis and monitoring EGFR gene mutations in advanced non-small cell lung cancer

Paola Bordi, Marzia Del Re, Romano Danesi, Marcello Tiseo

Novel radiotherapy approaches for lung cancer: combining radiation therapy with targeted and immunotherapies

Charles B. Simone II, Stuart H. Burri, John H. Heinzerling

Angiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC)

Richard D. Hall, Tri M. Le, Daniel E. Haggstrom, Ryan D. Gentzler

Original Article

Prognostic value of Twist in lung cancer: systematic review and meta-analysis

Junli Zeng, Ping Zhan, Guannan Wu, Wen Yang, Wenjun Liang, Tangfeng Lv, Yong Song

BRAF mutations in non-small cell lung cancer

Peter P. Luk, Bing Yu, Chiu Chin Ng, Belinda Mercorella, Christina Selinger, Trina Lum, Steven Kao, Sandra A. O’Toole, Wendy A. Cooper

The suitability of small biopsy and cytology specimens for EGFR and other mutation testing in non-small cell lung cancer

Shu Wang, Bing Yu, Chiu Chin Ng, Belinda Mercorella, Christina I. Selinger, Sandra A. O’Toole, Wendy A. Cooper

Itraconazole can inhibit malignant pleural effusion by suppressing lymphangiogenesis in mice

Yunfen Wang, Yanwen Yao, Hongbin Liu, Xingqun Ma, Tangfeng Lv, Dongmei Yuan, Xinwu Xiao, Jie Yin, Yong Song

Ratio of maximum standardized uptake value to primary tumor size is a prognostic factor in patients with advanced non-small cell lung cancer

Fangfang Chen, Yanwen Yao, Chunyan Ma, Xingqun Ma, Zhaofeng Wang, Tangfeng Lv, Xinwu Xiao, Jie Yin, Yong Song

Advanced proton beam dosimetry part II: Monte Carlo vs. pencil beam-based planning for lung cancer

Dominic Maes, Jatinder Saini, Jing Zeng, Ramesh Rengan, Tony Wong, Stephen R. Bowen

The cytokinesis-blocked micronucleus assay as a novel biomarker for selection of lung cancer screening participants

Randa A. El-Zein, Carol J. Etzel, Reginald F. Munden

The use of TCP based EUD to rank and compare lung radiotherapy plans: in-silico study to evaluate the correlation between TCP with physical quality indices

Abdulhamid Chaikh, Jacques Balosso

Review Article

Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer

Takashi Kohno, Takashi Nakaoku, Koji Tsuta, Katsuya Tsuchihara, Shingo Matsumoto, Kiyotaka Yoh, Koichi Goto

Overview of clinicopathologic features of ALK-rearranged lung adenocarcinoma and current diagnostic testing for ALK rearrangement

Hyojin Kim, Jin-Haeng Chung

Neoadjuvant and adjuvant epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer

Haoran Zhai, Wenzhao Zhong, Xuening Yang, Yi-Long Wu

Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations—a review

Erin L. Stewart, Samuel Zhixing Tan, Geoffrey Liu, Ming-Sound Tsao

Clinical trials for lung cancer in China

Fei-Yu Niu, Wen-Zhao Zhong, Qing Zhou, Yi-Long Wu

Recurrence after surgery in patients with NSCLC

Hidetaka Uramoto, Fumihiro Tanaka

Prognostic markers in lung cancer: is it ready for prime time?

Chang-Qi Zhu, Ming-Sound Tsao

Potential biomarkers for lung cancer screening

Gabriella Sozzi, Mattia Boeri

Particle therapy in non-small cell lung cancer

Zhongxing Liao, Charles B. Simone II

Computer Aided Nodule Analysis and Risk Yield (CANARY) characterization of adenocarcinoma: radiologic biopsy, risk stratification and future directions

Ryan Clay, Srinivasan Rajagopalan, Ronald Karwoski, Fabien Maldonado, Tobias Peikert, Brian Bartholmai

Immunotherapy and radiation therapy for operable early stage and locally advanced non-small cell lung cancer

Neil K. Taunk, Andreas Rimner, Melissa Culligan, Joseph S. Friedberg, Julie Brahmer, Jamie Chaft

Combining immunotherapy and radiation therapy for small cell lung cancer and thymic tumors

Suchit H. Patel, Andreas Rimner, Roger B. Cohen

Intraoperative near-infrared imaging of mesothelioma

Gregory Thomas Kennedy, Andrew Newton, Jarrod Predina, Sunil Singhal

BAP1, a tumor suppressor gene driving malignant mesothelioma

Mitchell Cheung, Joseph R. Testa

Uncovering the immune tumor microenvironment in non-small cell lung cancer to understand response rates to checkpoint blockade and radiation

Jonathan E. Schoenhals, Steven N. Seyedin, Clark Anderson, Eric D. Brooks, Yun R. Li, Ahmed I. Younes, Sharareh Niknam, Ailin Li, Hampartsoum B. Barsoumian, Maria Angelica Cortez, James W. Welsh

Diagnostic and prognostic biomarkers for malignant mesothelioma: an update

Zhongjian Chen, Giovanni Gaudino, Harvey I. Pass, Michele Carbone, Haining Yang

Immunotherapy for malignant pleural mesothelioma: current status and future directions

Jordan Dozier, Hua Zheng, Prasad S. Adusumilli

Biology and clinical significance of circulating tumor cell subpopulations in lung cancer

Linda O’Flaherty, Harriet Wikman, Klaus Pantel

Routine clinical use of circulating tumor cells for diagnosis of mutations and chromosomal rearrangements in non-small cell lung cancer—ready for prime-time?

Emma Pailler, Vincent Faugeroux, Marianne Oulhen, Cyril Catelain, Françoise Farace

Challenges and unanswered questions for the next decade of circulating tumour cell research in lung cancer

Sumitra Mohan, Francesca Chemi, Ged Brady

Biophysical technologies for understanding circulating tumor cell biology and metastasis

Derrick W. Su, Jorge Nieva

Clinical utility of circulating tumor cells in patients with non-small-cell lung cancer

Marianna Gallo, Antonella De Luca, Monica Rosaria Maiello, Amelia D’Alessio, Claudia Esposito, Nicoletta Chicchinelli, Laura Forgione, Maria Carmela Piccirillo, Gaetano Rocco, Alessandro Morabito, Gerardo Botti, Nicola Normanno

Integrating immunotherapy into chemoradiation regimens for medically inoperable locally advanced non-small cell lung cancer

Salma K. Jabbour, Abigail T. Berman, Charles B. Simone II

Editorial

An alternative way to initiate Notch1 signaling in non-small cell lung cancer

Yi-Lin Yang, David Jablons, Liang You

Combination MET- and EGFR-directed therapy in MET-overexpressing non-small cell lung cancers: time to move on to better biomarkers?

Fernando C. Santini, Siddharth Kunte, Alexander Drilon

Systematic Review and Meta-analysis

Association of the metformin with the risk of lung cancer: a meta-analysis

Li Wang, Yong Song, Guan-Nan Wu, Dong-Mei Yuan

China Lung Cancer Research Highlight

Dll4/Notch1 signaling from tip/stalk endothelial cell specification to stroma-dependent lung tumor inhibition: a flavor of Dll4/Notch1 pleiotropy in tumor cell biology

Maria Felice Brizzi, Paola Defilippi

Editorials

Dulanermin in cancer therapy: Still much to do

Cristina Quintavalle, Gerolama Condorelli

Review Articles

EGFR molecular testing in African-American non-small cell lung cancer patients - a review of discrepant data

Bradley T. Clifford, Pingfu Fu, Nathan A. Pennell, Balazs Halmos, Rom S. Leidner

Copy number gains of FGFR1 and 3q chromosome in squamous cell carcinoma of the lung

Pedro Mendez, Jose Luis Ramirez

Role of HGF/MET axis in resistance of lung cancer to contemporary management

Kanwal Pratap Singh Raghav, Ana Maria Gonzalez-Angulo, George R. Blumenschein Jr

Circulating soluble intercellular adhesion Molecule-1 in lung cancer: a systematic review

Xiaoling Gu, Chunyan Ma, Dongmei Yuan, Yong Song

Ceritinib

Clinical development and approval of second generation ALK inhibitors for ALK rearranged lung cancer

Daniel B. Costa

Onartuzumab plus erlotinib

Targeting MET in NSCLC: looking for a needle in a haystack

Lorenza Landi, Federico Cappuzzo

Nivolumab

Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients with advanced non-small cell lung cancer

Arun Rajan, James L. Gulley

Brief Report

The role of Imaging and Radiation Oncology Core for precision medicine era of clinical trial

Ying Xiao, Mark Rosen

Review Article on Update on Pathology and Predictive Biomarkers of Lung Cancer

Biology of invasive mucinous adenocarcinoma of the lung

Yoon Jin Cha, Hyo Sup Shim

Immunohistochemistry for predictive biomarkers in non-small cell lung cancer

Mari Mino- Kenudson

Below are the latest Translational Lung Cancer Research articles published online ahead of print publication.

Original Article

Tumoral PD-L1 does not impact time to treatment discontinuation in EGFR mutated non-small cell lung cancer patients treated with EGFR tyrosine kinase inhibitor—a Danish cohort study

Julie Gabe Dissing, Maiken Parm Ulhøi, Boe Sandahl Sorensen, Peter Meldgaard

Adjuvant treatment for patients with incidentally resected limited disease small cell lung cancer—a retrospective study

Kai-Qi Jin, Xiao-Gang Liu, Yan-Hua Guo, Chun-Xiao Wu, Jie Dai, Jia-Qi Li, Fabrizio Minervini, Mara B. Antonoff, Alex Friedlaender, Alfredo Addeo, Gregor J. Kocher, Francesco Grossi, Yu-Ming Zhu, Peng Zhang, Ge-Ning Jiang

USO1 expression is dysregulated in non-small cell lung cancer

Anna Keogh, Lisa Ryan, Mutaz M. Nur, Anne-Marie Baird, Siobhan Nicholson, Sinéad Cuffe, Gerard J. Fitzmaurice, Ronan Ryan, Vincent K. Young, Stephen P. Finn, Steven G. Gray

Development and validation of a polygenic hazard score to predict prognosis and adjuvant chemotherapy benefit in early-stage non- small cell lung cancer

Dan-Hua Li, Yong-Qiao He, Tong-Min Wang, Wen-Qiong Xue, Chang-Mi Deng, Da-Wei Yang, Wen-Li Zhang, Zi-Yi Wu, Lian-Jing Cao, Si-Qi Dong, Yi-Jing Jia, Lei-Lei Yuan, Lu-Ting Luo, Yan-Xia Wu, Xia-Ting Tong, Jiang-Bo Zhang, Mei-Qi Zheng, Ting Zhou, Xiao-Hui Zheng, Xi-Zhao Li, Pei-Fen Zhang, Shao-Dan Zhang, Ye-Zhu Hu, Xun Cao, Xin Wang, Wei-Hua Jia

Changes in serum transforming growth factor-beta concentration as a predictive factor for radiation-induced lung injury onset in radiotherapy-treated patients with locally advanced lung cancer

Yurie Seto, Yoshiko Kaneko, Takako Mouri, Daisuke Shimizu, Yoshie Morimoto, Shinsaku Tokuda, Masahiro Iwasaku, Tadaaki Yamada, Koichi Takayama

Clinical impact of amrubicin monotherapy in patients with relapsed small cell lung cancer: a multicenter retrospective study

Sayaka Uda, Tadaaki Yamada, Akihiro Yoshimura, Yasuhiro Goto, Kohei Yoshimine, Yoichi Nakamura, Shinsuke Shiotsu, Takashi Yokoi, Nobuyo Tamiya, Hideharu Kimura, Yusuke Chihara, Yukihiro Umeda, Miiru Izumi, Takayuki Takeda, Takahiro Yamada, Makoto Hibino, Osamu Hiranuma, Kazuhiro Ito, Asuka Okada, Shuji Osugi, Yoshizumi Takemura, Hiroshi Ishii, Kenji Chibana, Isao Hasegawa, Yoshie Morimoto, Masahiro Iwasaku, Shinsaku Tokuda, Koichi Takayama

Lung function impairment in the German Lung Cancer Screening Study (LUSI): prevalence, symptoms, and associations with lung cancer risk, tumor histology and all-cause mortality

Rudolf Kaaks, Evangelia Christodoulou, Erna Motsch, Verena Katzke, Mark O. Wielpütz, Hans-Ulrich Kauczor, Claus Peter Heussel, Monika Eichinger, Stefan Delorme

FDG PET and CT radiomics in diagnosis and prognosis of non-small-cell lung cancer

Pascal Hannequin, Chantal Decroisette, Pascale Kermanach, Giulia Berardi, Vincent Bourbonne

Plasma RNA profiling unveils transcriptional signatures associated with resistance to osimertinib in EGFR T790M positive non-small cell lung cancer patients

Andrey Alexeyenko, Odd Terje Brustugun, Inger Johanne Zwicky Eide, Radosveta Gencheva, Zeinab Kosibaty, Yi Lai, Luigi de Petris, Georgios Tsakonas, Oscar Grundberg, Bo Franzen, Kristina Viktorsson, Rolf Lewensohn, Per Hydbring, Simon Ekman

Impact of gender on response to immune checkpoint inhibitors in patients with non-small cell lung cancer undergoing second- or later-line treatment

Myeong Geun Choi, Chang-Min Choi, Dae Ho Lee, Sang-We Kim, Shinkyo Yoon, Wonjun Ji, Jae Cheol Lee

Comprehensive analysis of T cell receptor repertoire in patients with KRAS mutant non-small cell lung cancer

Yadong Wang, Ling Peng, Ming Zhao, Yuanyuan Xiong, Jianchao Xue, Bowen Li, Zhicheng Huang, Xinyu Liu, Xiaoying Yang, Yang Song, Zhongxing Bing, Chao Guo, Zhenhuan Tian, Chao Gao, Lei Cao, Zhili Cao, Ji Li, Xu Jiang, Xiaoyan Si, Li Zhang, Xiaoguang Li, Zhibo Zheng, Mengmeng Song, Rongrong Chen, Wan-Teck Lim, Alberto Pavan, Atocha Romero, Naixin Liang, Huaxia Yang, Shanqing Li

Impact of treatment line on risks and benefits of immune checkpoint inhibitor in patients with advanced non-small cell lung cancer and interstitial lung disease: a systematic review and meta-analysis of cohort studies

Kinnosuke Matsumoto, Takayuki Shiroyama, Tomoki Kuge, Kotaro Miyake, Yuji Yamamoto, Midori Yoneda, Makoto Yamamoto, Yujiro Naito, Yasuhiko Suga, Kiyoharu Fukushima, Shohei Koyama, Kota Iwahori, Haruhiko Hirata, Izumi Nagatomo, Yoshito Takeda, Atsushi Kumanogoh

Value of 18-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) in the differential diagnosis of sarcoidosis and lung cancer with lymph node metastasis: a retrospective study

Xianqiu Chen, Xin Xu, Serafeim Chrysikos, Mengmeng Zhao, Ying Zhou

Efficacy and safety of amrubicin therapy after chemoimmunotherapy in small cell lung cancer patients

Kohei Kushiro, Satoshi Watanabe, Yuka Goto, Toshiya Fujisaki, Naohiro Yanagimura, Aya Ohtsubo, Satoshi Shoji, Koichiro Nozaki, Tomohiro Tanaka, Yu Saida, Yusuke Sato, Takeshi Ota, Jun Koshio, Yoshiki Hayashi, Takao Miyabayashi, Naoya Matsumoto, Kosuke Ichikawa, Kenichi Koyama, Toshiaki Kikuchi

PTS is activated by ATF4 and promotes lung adenocarcinoma development via the Wnt pathway

Wei Ma, Chao Wang, Ruzhen Li, Zhaohui Han, Yuanzhu Jiang, Xiangwei Zhang, Duilio Divisi, Enrico Capobianco, Lin Zhang, Wei Dong

Review Article

Multiple mutations in the EGFR gene in lung cancer: a systematic review

Juan Pablo Castañeda-González, Juan José Chaves, Rafael Parra-Medina

Editorial

Exploring immune checkpoint inhibition in combination with anti-angiogenic therapy for patients with EGFR- or ALK-positive advanced non-small cell lung cancer

Andrea De Giglio, Alessandro Di Federico, Giulio Metro

Complex glandular pattern as an independent predictor of survival probability in lung adenocarcinoma

Per Hydbring

Case Report

MYC amplification-conferred primary resistance to capmatinib in a MET-amplified NSCLC patient: a case report

Wonyoung Choi, Kyung-Chae Jeong, Seog-Yun Park, Sunshin Kim, Eun Hye Kang, Mihwa Hwang, Ji-Youn Han

Cytokine release syndrome in a patient with non-small-cell lung cancer on ipilimumab and nivolumab maintenance therapy after vaccination with the mRNA-1273 vaccine: a case report

Toshiyuki Sumi, Yuta Koshino, Haruhiko Michimata, Daiki Nagayama, Hiroki Watanabe, Yuichi Yamada, Hirofumi Chiba

Consensus

International consensus on radiotherapy in metastatic non-small cell lung cancer

Zhengfei Zhu, Jianjiao Ni, Xuwei Cai, Shengfa Su, Hongqing Zhuang, Zhenzhou Yang, Ming Chen, Shenglin Ma, Conghua Xie, Yaping Xu, Jiancheng Li, Hong Ge, Anwen Liu, Lujun Zhao, Chuangzhou Rao, Congying Xie, Nan Bi, Zhouguang Hui, Guangying Zhu, Zhiyong Yuan, Jun Wang, Lina Zhao, Wei Zhou, Chai Hong Rim, Arturo Navarro-Martin, Ben G. L. Vanneste, Dirk De Ruysscher, J. Isabelle Choi, Jacek Jassem, Joe Y. Chang, Lucyna Kepka, Lukas Käsmann, Michael T. Milano, Paul Van Houtte, Rafal Suwinski, Alberto Traverso, Hiroshi Doi, Yang-Gun Suh, Georges Noël, Natsuo Tomita, Roman O. Kowalchuk, Terence T. Sio, Baosheng Li, Bing Lu, Xiaolong Fu

iMDT Corner

Circulating tumor DNA accurately predicts disease progression and genotype alterations in postoperative adjuvant EGFR-TKI resistance: a case report

Zhen Zeng, Chengwu Liu, Senyi Deng, Feng Lin, Hatim Husain, Mariacarmela Santarpia, Lunxu Liu

Journal Highlight more

Translational Lung Cancer Research is an international, peer-reviewed, open-access journal indexed by Science Citation Index Expanded (SCIE) and PubMed/PubMed Central, focusing on cutting-edge development on the transition from preclinical to clinical research, including but not limited to multimodality therapy, markers, imaging, tumor biology, pathology, chemoprevention, and technical advances related to lung cancer and relevant thoracic diseases.